secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001104659-25-107426
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance Q3 revenue $68M (+13% QoQ), margin 43%; lifileucel NSCLC data durable
-----------------------------------------------------------------------------

- Q3 2025 product revenue ~$68M, up 13% sequentially; gross margin 43% on ~$39M cost of sales.
- Cash and investments ~$307M; expected to fund operations into Q2 2027.
- Full-year 2025 revenue guidance reaffirmed at $250-300M.
- Lifileucel in NSCLC: ORR 26%, median DOR not reached at >25 months; IOV-LUN-202 enrollment to complete in 2026.
- Amtagvi now at >80 U.S. authorized treatment centers; Health Canada approval in August 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925107426/0001104659-25-107426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925107426/tm2530236d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer